# A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)

> **NCT06191328** · NA · UNKNOWN · sponsor: **Yufan Wang** · enrollment: 40 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Chiglitazar sodium

## Key facts

- **NCT ID:** NCT06191328
- **Lead sponsor:** Yufan Wang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-31
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06191328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06191328, "A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06191328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*